Novo Nordisk stock gains 2.89 percent after-hours to EUR 34.18
Published on 10/07/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock gains 2.89 percent after-hours to EUR 34.18 versus the EUR 33.22 prior close at Lang & Schwarz on October 7, 2026. The quote was recorded at 5:43 p.m. CEST.
Trading after the Xetra close
Lang & Schwarz showed a bid of EUR 34.06 and an ask of EUR 34.30. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
Share repurchase program
In a press release dated October 5, 2026, Novo Nordisk said it had repurchased 36,604,179 B shares since February 4, 2026, at an average price of DKK 279.95 per share. The transaction value was DKK 10,247,270,869, under a broader repurchase program of up to DKK 15 billion. The company said its treasury holdings totaled 50,644,876 B shares, equal to 1.1 percent of share capital. The figures were reported in a Globenewswire release.
Denecimig review remains ongoing
Novo Nordisk said on October 2, 2026, that the FDA review of its denecimig application for hemophilia A remained ongoing, with facility remediation activities extending the review. The FDA had not communicated a new regulatory timetable, while Novo said the additional review time did not affect its 2026 financial outlook. The company aims to launch denecimig in the United States in the first half of 2027, pending a regulatory decision, according to a Globenewswire release.
